Variant Summary
- HGVS
- —
- Variant Type(s)
- loss_of_function_variant
- Evidence Items
- 38
Evidence Level Distribution
Level B: 15Level C: 2Level D: 21
Evidence Items
Showing CIViC evidence rows where gene = PTEN and variant = Loss.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Everolimus | 4 |
| D | Predictive | Supports | Sensitivity/Response | Prostate Cancer | Temsirolimus | 4 |
| D | Predictive | Supports | Resistance | Melanoma | Vemurafenib | 4 |
| B | Predictive | Supports | Resistance | Bladder Carcinoma | Everolimus | 4 |
| D | Predictive | Supports | Resistance | Breast Cancer | Alpelisib | 4 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Lapatinib | 4 |
| B | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 3 |
| B | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,PI3K/BET Inhibitor LY294002 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Capivasertib | 3 |
| D | Predictive | Does Not Support | Sensitivity/Response | Breast Cancer | Everolimus,MTOR Kinase Inhibitor PP242 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Endometrial Cancer | Temsirolimus | 3 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Pictilisib | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Cancer | Everolimus | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 3 |
| C | Predictive | Supports | Sensitivity/Response | Cancer | Paclitaxel,Carboplatin,Buparlisib | 3 |
| B | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 3 |
| B | Predictive | Does Not Support | Resistance | Endometrial Cancer | Ridaforolimus,Temsirolimus | 3 |
| D | Predictive | Supports | Resistance | Stomach Cancer | Docetaxel | 2 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| D | Predictive | Supports | Resistance | Ovarian Cancer | Cisplatin | 2 |
| B | Predictive | Supports | Resistance | Stomach Carcinoma | Chemotherapy | 2 |
| B | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| B | Predictive | Supports | Resistance | Breast Cancer | Trastuzumab | 2 |
| D | Predictive | Does Not Support | Sensitivity/Response | Breast Cancer | Pictilisib | 2 |
| B | Predictive | Does Not Support | Sensitivity/Response | Solid Tumor | Paclitaxel,Buparlisib,Carboplatin | 2 |
| D | Predictive | Supports | Sensitivity/Response | Melanoma | Uprosertib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | PI3Kbeta Inhibitor AZD8186 | 2 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib,Lapatinib | 2 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib,Trastuzumab | 2 |
| B | Predictive | Supports | Resistance | Gastric Adenocarcinoma | Trastuzumab,Lapatinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Pancreatic Carcinoma | Akt Inhibitor MK2206 | 2 |
| D | Predictive | Supports | Sensitivity/Response | Stomach Cancer | Docetaxel,Capivasertib | 1 |
| B | Predictive | Supports | Resistance | Breast Cancer | Trastuzumab | 1 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | PI-103 | 1 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | PI3Ka/Di | 1 |